SLC27A5 and cancer: Collectively, our metabolic analyses implied that FATP5 loss augments glucose flux to support the glycolytic pathway and induce ATP production, inhibiting AMPK phosphorylation and activating mTOR signaling to promote EMT and cancer cell metastasis.